Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05312710 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of APG-157 in Head and Neck Cancer
A Phase 2 study of Head and Neck Cancer and Squamous Cell Carcinoma of the Oropharynx, sponsored by Aveta Biomics.
- Active
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 2
- Study locations
NCT05312710 is a Phase 2 study of Head and Neck Cancer and Squamous Cell Carcinoma of the Oropharynx that is active but no longer recruiting, run by Aveta Biomics. The registered enrollment target is 24 participants, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05312710, a Phase 2 study of Head and Neck Cancer and Squamous Cell Carcinoma of the Oropharynx, is active but no longer recruiting, sponsored by Aveta Biomics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this clinical research study is to study safety and efficacy of orally administered APG-157 as the neoadjuvant/induction therapy in newly diagnosed, locally advanced patients with Head \& Neck Cancer of oral cavity and/or oropharynx. The study hypothesis is that neoadjuvant use of APG-157 will reduce the tumor burden prior to any definitive therapy to improve the outcomes over current standard of care.
Conditions Studied
Interventions
- DRUG APG-157
Study Locations (2)
California
- VAGLAHS, West Los Angeles - Los Angeles
Florida
- University of Miami Sylvester Comprehensive Cancer Center - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2022-04-22 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05312710
The ClinicalTrials.gov registry entry for NCT05312710 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (91% lower). The listed sponsor is Aveta Biomics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 1 intervention - of which APG-157 is the first listed.
NCT05312710 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Florida.
Frequently Asked Questions
What is clinical trial NCT05312710 about?
NCT05312710 is a clinical study titled "Safety and Efficacy of APG-157 in Head and Neck Cancer". The purpose of this clinical research study is to study safety and efficacy of orally administered APG-157 as the neoadjuvant/induction therapy in newly diagnosed, locally advanced patients with Head \& Neck Cancer of oral cavity and/or oropharynx. The study hypothesis is that neoadjuvant use of AP...
What is the current status of trial NCT05312710?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2022-04-22. Estimated completion is 2026-12.
What conditions does trial NCT05312710 study?
This clinical trial studies the following conditions: Head and Neck Cancer, Squamous Cell Carcinoma of the Oropharynx, Squamous Cell Carcinoma of Oral Cavity.
What interventions are being tested in trial NCT05312710?
The interventions under investigation include: APG-157 (DRUG).
Who is sponsoring clinical trial NCT05312710?
This trial is sponsored by Aveta Biomics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05312710 being conducted?
This trial has 2 study locations across California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase II Panitumumab-IRDye800 in Head & Neck Cancer
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
RECRUITING · Phase 2
-
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
RECRUITING · Phase 2
-
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
RECRUITING · Phase 2
-
A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)
RECRUITING · Phase 2
Explore more on PlainTrial
Head and Neck Cancer
All registered trials for this condition
Squamous Cell Carcinoma of the Oropharynx
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.